El Teatro Total de Walter Gropius y Erwin Piscator
SEGUNDA FASE
A.S. Othman is supported by a Skim Latihan Akademik IPTA - SLAI (Ministry of Higher Education, Malaysia). C. M. Mogollon was supported by Colciencias Ph.D. fellowship (Call 568 from 2012 Resolution 01218 Bogotá, Colombia).
Generation and pr
otective ef
ficacy of ‘self-adjuvanting’ GAP
4
REFERENCES
1. Bijker, E.M., et al., Novel approaches to whole sporozoite vaccination against malaria. Vaccine, 2015. 33(52): p. 7462-7468. 2. Richie, T.L., et al., Progress with Plasmodium
falciparum sporozoite (PfSPZ)-based malaria vaccines. Vaccine, 2015. 33(52): p. 7452-7461. 3. Hollingdale, M.R. and M. Sedegah,
Development of whole sporozoite malaria vaccines. Expert Review of Vaccines, 2017. 16(1): p. 45-54.
4. Seder, R.A., et al., Protection Against Malaria by Intravenous Immunization with a Nonreplicating Sporozoite Vaccine. Science, 2013. 341(6152): p. 1359-1365. 5. Hoffman, S.L., et al., Protection of
humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. Journal of Infectious Diseases, 2002. 185(8): p. 1155-1164. 6. Roestenberg, M., et al., Protection
against a Malaria Challenge by Sporozoite Inoculation. New England Journal of Medicine, 2009. 361(5): p. 468-477.
7. Sissoko, M.S., et al., Safety and efficacy of PfSPZ Vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial. Lancet Infectious Diseases, 2017. 17(5): p. 498-509.
8. Butler, N.S., et al., Superior Antimalarial Immunity after Vaccination with Late Liver Stage- Arresting Genetically Attenuated Parasites. Cell Host & Microbe, 2011. 9(6): p. 451-462.
9. Kreutzfeld, O., K. Müller, and K. Matuschewski, Engineering of Genetically Arrested Parasites (GAPs) For a Precision Malaria Vaccine. Frontiers in Cellular and Infection Microbiology, 2017. 7: p. 198. 10. Singer, M. and F. Frischknecht, Time
for Genome Editing: Next Generation Attenuated Malaria Parasites. Trends in Parasitology, 2017. 33(3): p. 202-213.
11. van Schaijk, B.C.L., et al., A genetically attenuated malaria vaccine candidate based on P. falciparum b9/slarp gene- deficient sporozoites. Elife, 2014. 3. 12. Mikolajczak, S.A., et al., A Next-generation
Genetically Attenuated Plasmodium falciparum Parasite Created by Triple Gene Deletion. Molecular Therapy, 2014. 22(9): p. 1707-1715. 13. Kublin, J.G., et al., Complete attenuation
of genetically engineered Plasmodium falciparum sporozoites in human subjects. Science Translational Medicine, 2017. 9(371). 14. Ishizuka, A.S., et al., Protection against malaria
at 1 year and immune correlates following PfSPZ vaccination (vol 22, pg 614, 2016). Nature Medicine, 2016. 22(6): p. 692-692. 15. Lyke, K.E., et al., Attenuated PfSPZ Vaccine
induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection. Proceedings of the National Academy of Sciences of the United States of America, 2017. 114(10): p. 2711-2716. 16. Van Braeckel-Budimir, N. and J.T. Harty,
CD8 T-cell-mediated protection against liver-stage malaria: lessons from a mouse model. Frontiers in Microbiology, 2014. 5. 17. Doll, K.L. and J.T. Harty, Correlates of protective
immunity following whole sporozoite vaccination against malaria. Immunologic Research, 2014. 59(1-3): p. 166-176.
18. Van Braeckel-Budimir, N., S.P. Kurup, and J.T. Harty, Regulatory issues in immunity to liver and blood-stage malaria. Current Opinion in Immunology, 2016. 42: p. 91-97. 19. Khan, S.M., et al., Genetic engineering
of attenuated malaria parasites for vaccination. Current Opinion in Biotechnology, 2012. 23(6): p. 908-916. 20. Gonzalez-Aseguinolaza, G., et al., Natural
killer T cell ligand alpha-galactosylceramide enhances protective immunity induced by malaria vaccines. Journal of Experimental Medicine, 2002. 195(5): p. 617-624.
Generation and pr
otective ef
ficacy of ‘self-adjuvanting’ GAP
4
21. Li, X.M., et al., Colocalization of a CD1d-Binding Glycolipid with a Radiation- Attenuated Sporozoite Vaccine in Lymph Node-Resident Dendritic Cells for a Robust Adjuvant Effect. Journal of Immunology, 2015. 195(6): p. 2710-2721. 22. Othman, A.S., et al., OX40 stimulation
enhances protective immune responses induced after vaccination with attenuated malaria parasites. Frontiers in Cellular and Infection Microbiology, 2018. (In press). 23. Anderson, R.J., et al., A self-adjuvanting
vaccine induces cytotoxic T lymphocytes that suppress allergy. Nature Chemical Biology, 2014. 10(11): p. 943-949.
24. Brown, L.E. and D.C. Jackson, Lipid-based self-adjuvanting vaccines. Curr Drug Deliv, 2005. 2(4): p. 383-93.
25. Tiptiri-Kourpeti, A., et al., DNA vaccines to attack cancer: Strategies for improving immunogenicity and efficacy. Pharmacology & Therapeutics, 2016. 165: p. 32-49. 26. Moyle, P.M., Biotechnology approaches to
produce potent, self-adjuvanting antigen- adjuvant fusion protein subunit vaccines. Biotechnology Advances, 2017. 35(3): p. 375-389.
27. Chauhan, N., et al., An overview of adjuvants utilized in prophylactic vaccine formulation as immunomodulators. Expert Review of Vaccines, 2017. 16(5): p. 491-502. 28. McDonald, D.M., S.N. Byrne, and
R.J. Payne, Synthetic self-adjuvanting glycopeptide cancer vaccines. Frontiers in Chemistry, 2015. 3.
29. Kalnin, K., et al., Incorporation of RG1 epitope concatemers into a self-adjuvanting Flagellin-L2 vaccine broaden durable protection against cutaneous challenge with diverse human papillomavirus genotypes. Vaccine, 2017. 35(37): p. 4942-4951. 30. Chua, B.Y., et al., A self-adjuvanting
lipopeptide-based vaccine candidate for the treatment of hepatitis C virus infection. Vaccine, 2008. 26(37): p. 4866-4875.
31. Gomez-Samblas, M., et al., Self-adjuvanting C18 lipid vinil sulfone-PP2A vaccine: study of the induced immunomodulation against Trichuris muris infection. Open Biology, 2017. 7(4).
32. Azmi, F., et al., Self-adjuvanting vaccine against group A streptococcus: Application of fibrillized peptide and immunostimulatory lipid as adjuvant. Bioorganic & Medicinal Chemistry, 2014. 22(22): p. 6401-6408. 33. Moyle, P.M. and I. Toth, Self-adjuvanting
lipopeptide vaccines. Current Medicinal Chemistry, 2008. 15(5): p. 506-516.
34. Carapau, D., et al., Protective Humoral Immunity Elicited by a Needle-Free Malaria Vaccine Comprised of a Chimeric Plasmodium falciparum Circumsporozoite Protein and a Toll-Like Receptor 5 Agonist, Flagellin. Infection and Immunity, 2013. 81(12): p. 4350-4362. 35. Cui, B.F., et al., Flagellin as
a vaccine adjuvant. Expert Review of Vaccines, 2018. 17(4): p. 335-349.
36. Plant, A. and N.A. Williams, Modulation of the immune response by the cholera-like enterotoxins. Current Topics in Medicinal Chemistry, 2004. 4(5): p. 509-519.
37. Stratmann, T., Cholera Toxin Subunit B as Adjuvant-An Accelerator in Protective Immunity and a Break in Autoimmunity. Vaccines, 2015. 3(3): p. 579-596.
38. Bolhassani, A. and S. Rafati, Heat- shock proteins as powerful weapons in vaccine development. Expert Review of Vaccines, 2008. 7(8): p. 1185-1199.
39. Strbo, N., et al., Secreted heat shock protein gp96-Ig: next-generation vaccines for cancer and infectious diseases. Immunologic Research, 2013. 57(1-3): p. 311-325.
40. Ding, Y., et al., Heat‐Shock Protein gp96 Enhances T Cell Responses and Protective Potential to Bacillus Calmette‐
Guérin Vaccine. Scandinavian Journal of Immunology, 2016. 84(4): p. 222-228.
Generation and pr
otective ef
ficacy of ‘self-adjuvanting’ GAP
4
41. Jung, I.D., et al., Enhancement of Tumor- Specific T Cell–Mediated Immunity in Dendritic Cell–Based Vaccines by <em>Mycobacterium tuberculosis</ em> Heat Shock Protein X. The Journal of Immunology, 2014. 193(3): p. 1233. 42. Kim, H.Y., et al., Heat shock protein X
purified from Mycobacterium tuberculosis enhances the efficacy of dendritic cells-based immunotherapy for the treatment of allergic asthma. Bmb Reports, 2015. 48(3): p. 178-183. 43. Andersen-Nissen, E., et al., Evasion of
Toll-like receptor 5 by flagellated bacteria. Proceedings of the National Academy of Sciences of the United States of America, 2005. 102(26): p. 9247-9252. 44. Kang, X.L., Z.M. Pan, and X.N. Jiao, Amino
acids 89-96 of Salmonella flagellin: a key site for its adjuvant effect independent of the TLR5 signaling pathway. Cellular & Molecular Immunology, 2017. 14(12): p. 1023-1025. 45. Lin, J.W., et al., The Subcellular Location
of Ovalbumin in Plasmodium berghei Blood Stages Influences the Magnitude of T-Cell Responses. Infection and Immunity, 2014. 82(11): p. 4654-4665. 46. Montagna, G.N., et al., Antigen Export
during Liver Infection of the Malaria Parasite Augments Protective Immunity. Mbio, 2014. 5(4).
47. Lin, J.-w., et al., A Novel ‘Gene Insertion/Marker Out’ (GIMO) Method for Transgene Expression and Gene Complementation in Rodent Malaria Parasites. PLOS ONE, 2011. 6(12): p. e29289. 48. Salman, A.M., et al., Generation of
Transgenic Rodent Malaria Parasites Expressing Human Malaria Parasite Proteins, in Malaria Vaccines: Methods and Protocols, A. Vaughan, Editor. 2015, Springer New York: New York, NY. p. 257-286.
49. Haeberlein, S., et al., Protective immunity differs between routes of administration of attenuated malaria parasites independent of parasite liver load. Scientific Reports, 2017. 7. 50. Janse, C.J., J. Ramesar, and A.P. Waters, High-
efficiency transfection and drug selection
of genetically transformed blood stages of the rodent malaria parasite Plasmodium berghei. Nature Protocols, 2006. 1(1): p. 346-356. 51. Annoura, T., et al., Quantitative Analysis
of Plasmodium berghei Liver Stages by Bioluminescence Imaging, in Malaria: Methods and Protocols, R. Ménard, Editor. 2013, Humana Press: Totowa, NJ. p. 429-443. 52. Silvie, O., et al., Hepatocyte CD81 is
required for Plasmodium falciparum and Plasmodium yoelii sporozoite infectivity. Nature Medicine, 2003. 9(1): p. 93-96. 53. Hafalla, J.C.R., I.A. Cockburn, and F. Zavala,
Protective and pathogenic roles of CD8+T cells during malaria infection. Parasite Immunology, 2006. 28(1-2): p. 15-24. 54. Ploemen, I.H.J., et al., Visualisation and
Quantitative Analysis of the Rodent Malaria Liver Stage by Real Time Imaging. Plos One, 2009. 4(11).
55. Otto, T.D., et al., A comprehensive evaluation of rodent malaria parasite genomes and gene expression. Bmc Biology, 2014. 12.
56. Mueller, A.K., et al., Plasmodium liver stage developmental arrest by depletion of a protein at the parasite-host interface. Proceedings of the National Academy of Sciences of the United States of America, 2005. 102(8): p. 3022-3027. 57. Silvie, O., et al., Post-transcriptional silencing
of UIS4 in Plasmodium berghei sporozoites is important for host switch. Molecular Microbiology, 2014. 91(6): p. 1200-1213. 58. Silva, P.A.G.C., et al., Translational Control
of UIS4 Protein of the Host-Parasite Interface Is Mediated by the RNA Binding Protein Puf2 in Plasmodium berghei Sporozoites. Plos One, 2016. 11(1).
59. Tarun, A.S., et al., Protracted sterile protection with Plasmodium yoelii pre-erythrocytic genetically attenuated parasite malaria vaccines is independent of significant liver- stage persistence and is mediated by CD8(+) T cells. Journal of Infectious Diseases, 2007.
Generation and pr
otective ef
ficacy of ‘self-adjuvanting’ GAP